UNSPSC 51323108: Xenthiorate

This classification denotes an anti-lipidemic agent with the molecular formula C22H29NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0PM0Q96HVS, chemically known as 4-biphenylacetic acid, alpha-ethylthio-, s-(2-(diethylamino)ethyl) ester but generally known as xenthiorate, which bears US NIH Compound Identifier 6445348. European Medicines Agency schedules Xenthiorate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00105MIG.

UNSPSC 51323108 Xenthiorate, a Commodity code, represents pharmaceutical products and medications that state and local governments procure for emergency medical services, public health programs, and multistate cooperative purchasing agreements. Recent solicitations show state and local buyers acquiring specific injectable medications — epinephrine, labetalol, adenosine, and diltiazem — for emergency response; generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing networks; and exploring direct-to-manufacturer prescription fulfillment models to optimize pharmacy benefit management. The issuing bodies span city fire rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances. The scope ranges from discrete emergency medication line items with firm pricing and short delivery windows to large-volume pharmaceutical supply agreements negotiated through authorized wholesaler networks and managed via electronic data interchange systems.

Activity under the code concentrates in Florida and Minnesota, with emerging procurement in Texas. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (response deadline April 8, 2026; estimated contract value $40,000.00), requiring four specific medication line items with nine-month expiration windows, ten-day delivery, and a 5 percent Small Local Business Enterprise bid discount. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted March 27, 2026; deadline April 3, 2026) seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, an early-stage market intelligence gathering that will inform future formal procurement strategy.